XLON
FAB
Market cap16mUSD
Oct 09, Last price
10.00GBP
1D
0.00%
1Q
-9.09%
IPO
-93.51%
Name
Fusion Antibodies PLC
Chart & performance
P/E
—
P/S
5.93
EPS
—
Div yield, %
—
Shrs. gr., 5y
35.27%
Rev. gr., 5y
-12.72%
Revenues
2m
+7.38%
Net income
-1m
L-32.92%
CFO
-1m
L-18.70%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Key people
Simon Douglas
Non-Executive Chairman of the Board · since 2011
Stephen Smyth
Interim Chief Financial Officer and Company Secretary, Executive Director · since 2023
Richard Buick
Chief Scientific Officer, Executive Director · since 2021
Adrian Kinkaid
Chief Executive Officer, Executive Director · since 2022
Colin Walsh
Non-Executive Director · since 2007
Matthew Baker
Non-Executive Independent Director · since 2022
Legal address
C/O TUGHANS SOLICITORS
MARLBOROUGH HOUSE
30 VICTORIA STREET
BELFAST, BFS BT1 3GS
GB
MARLBOROUGH HOUSE
30 VICTORIA STREET
BELFAST, BFS BT1 3GS
GB
Headquarters
1 SPRINGBANK ROAD
SPRINGBANK INDUSTRIAL ESTATE
BELFAST, BFS BT17 0QL
GB
SPRINGBANK INDUSTRIAL ESTATE
BELFAST, BFS BT17 0QL
GB
Previous name
FUSION ANTIBODIES LIMITED
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||